Cellectis And Thermo Fisher Scientific Enter Into Agreements On TALEN, A Leading Gene Editing Technology
CARLSBAD, Calif. & PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA), a leader of engineered CART cell therapies, and Thermo Fisher Scientific announced today that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.
Help employers find you! Check out all the jobs and post your resume.